IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.
Steady: 0 in the last 7 days
Updated sep 28
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.IGC Pharma is using McGill University and Hamilton Health Sciences as clinical trial sites.1 source
- Both the FDA and the European Medicines Agency are reviewing deucrictibant for approval.Sub-event
Seeking FDA review and EMA support for lead drug candidate.1 source
Keep exploring
The entities involved
- FDA
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- Menarini Group and NewAmsterdam Pharma Company N.V. are collaborating on drug development, seeking marketing authorization in Europe through the EMA and EC process.
- Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
- Steriwave requires FDA approval for US market.
- Adam Craig reported positive results that could support FDA approval for a treatment.
- Allarity Therapeutics has established a facility in Horsholm, Northern Europe, and the FDA requires CLIA certification for biomarker testing.